Sr-89

Strontium -89 is a radioactive isotope of strontium and has a relatively long half-life (50 days).
Strontium-89 (89SrCl2) is the first radioactive drug used to treat primary and metastatic bone tumors. Strontium-89 emits pure beta radiation with an energy of 1.46 MeV. It has a long half-life (50 days) and can maintain its efficacy for a long time. Generally, the analgesic effect can be maintained for an average of 6 months after injection, and some can last for more than 1 year.